scholarly journals Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: failure of a lasting response to a second allogeneic transplant from the original donor

2008 ◽  
Vol 42 (9) ◽  
pp. 631-633 ◽  
Author(s):  
R J Cutting ◽  
E Welch ◽  
J Channer ◽  
Y Ezaydi ◽  
P Talley ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Initial Presentation ◽  
Allogeneic Transplant ◽  
Original Donor

scholarly journals Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4782-4782
Author(s):  
Nishi Shah ◽  
Appalanaidu Sasapu ◽  
Shebli Atrash ◽  
Joshi P Krishna ◽  
Laura F Hutchins ◽  
...  
Keyword(s):  
United States ◽  
Myelodysplastic Syndrome ◽  
American Indian ◽  
Racial Groups ◽  
Seer Database ◽  
Allogeneic Transplant ◽  
Myeloid Neoplasms ◽  
The Mean ◽  
Race Ethnicity ◽  
Hispanic White

Abstract Introduction: World Health Organization (WHO) classifies therapy-related myeloid neoplasms (t-MN) into therapy related acute myeloid leukemia (t-AML), therapy related myelodysplastic syndrome (t-MDS), and therapy related myelodysplastic syndrome/myeloproliferative neoplasms (t-MDS/MPN). These diseases are aggressive hematological malignancies and only allogeneic transplant offers the possibility of long-term remission. We performed retrospective analyses of Surveillance, Epidemiology, and End-Results (SEER) database to examine differences in incidence and survival outcomes of t-MN across different races and ethnicities in United States (US). Methods: Patients who developed t-MN following previous hematological or solid organ malignancies were included in the analyses. SEER registries classify race, ethnicity using 2000 US Census categories based on self- identification, medical records, death certificates and though linkage to Indian Health Service records. The race/ethnicity was categorized as non-Hispanic white (nHW), Hispanic white (HW), non-Hispanic Black (nHB), non-Hispanic Asian/Pacific islander (nHA/P), non- Hispanic American Indian/ Alaskan natives (nHI/A) and unknown groups (U). The patients were divided into various age group categories: <50 years, 50-59 years, 60-69 years, 70-79 years and >80 years. The statistical analyses were performed using SAS 9.4 software. Results: 13990 patients were reported to SEER database during 2000-2012 period with the diagnosis of t-MN. The total number of newly diagnosed t-MN in various racial groups was: nHW-11307, HW-900, nHB-1018, nHA/P-708, nHI/A -51 and U-6. There was higher reporting of non-Hodgkin lymphoma in females and lung/bronchial malignancies in males across all racial groups. Comparing different age groups, 50 months OS rates were: 2%, 6%, 13%,22% and 26% for groups >80 years, 70-79 years, 60-69 years, 50-59 years and <50 years, respectively. (figure 1). Males had worse OS when compared with females, however it was not significant after adjusting for age. The annual incidence of t-MN was highest amongst nHWs at 5.4 (5.3-5.4) per 100,000 and was lowest in American-Indian at 3.5 (3.0-4.0) per 100,000. The mean OS from the diagnosis of t-MN in nHW, HW, nHB, nHA/P and nHA/I was 11.1 mo, 12.35 mo, 11.86 mo, 12.1 mo and 11.41 mo respectively. When compared with HWs, nHWs had worse OS (p=<0.001). Similarly, when compared between HWs and nHBs, the mean OS was 12.35 months in HW population versus nHB population (OS=11.86 months) (p=<0.001). Overall, it was observed that HWs had better OS and presented with t-MN at younger age. Conclusion: In summary, the analyses of SEER database for t-MN revealed that t-MN developed in small proportion of patients exposed to cytotoxic agents or radiotherapy. nHWs non-had the highest incidence of reported t-MN, probably due to better access to healthcare and resources. There was statistically significant difference in the observed OS of HWs versus other ethnic groups. It appeared that the median age of diagnosis of t-MN in HW was 65 yrs, which made this racial group more likely to get definitive management for t-MN(allogeneic transplant). This might have contributed towards better overall survival in HW population. nHB group had statistically significant poor OS when compared with nHW or HW groups. The possible explanation could be, lack of access to healthcare, unable to get allogeneic transplant due to lack of donor availability or genetic variations such as polymorphisms in DNA repair enzymes and nucleotide excision repair pathways. The cancer survivors are living longer with novel treatment and are more likely to develop subsequent malignancies and population based studies are essential for identifying cohorts of at risk patients. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

scholarly journals Pulmonary Leukocytoclastic Vasculitis as an Initial Presentation of Myelodysplastic Syndrome

2016 ◽  
Vol 79 (4) ◽  
pp. 302 ◽  
Author(s):  
Seung Hyun Lee ◽  
Jae Hyung Kim ◽  
Sejin Park ◽  
Chang Youn Won ◽  
Joo-Hyun Lee ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Leukocytoclastic Vasculitis ◽  
Initial Presentation

WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients

2014 ◽  
Vol 94 (5) ◽  
pp. 761-769
Author(s):  
Liyuan Ma ◽  
Siguo Hao ◽  
Colin Diong ◽  
Yeow-Tee Goh ◽  
Sathish Gopalakrishnan ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Myelodysplastic Syndrome ◽  
Prognostic Indicator ◽  
Southeast Asian ◽  
Allogeneic Transplant ◽  
Asian Patients

scholarly journals Survival After Second Allogeneic Transplant Is Improved in Recipients by Using the Original Donor

2013 ◽  
Vol 19 (2) ◽  
pp. S309-S310
Author(s):  
Waseem Touma ◽  
Mark A. Schroeder ◽  
Ningying Wu ◽  
Keith Stockerl-Goldstein ◽  
Peter Westervelt ◽  
...  
Keyword(s):  
Allogeneic Transplant ◽  
Original Donor

scholarly journals Peripheral acute leukemia: high peripheral but low-marrow blast count

Blood ◽  
1989 ◽  
Vol 74 (5) ◽  
pp. 1758-1761
Author(s):  
JD Cason ◽  
JM Trujillo ◽  
EH Estey ◽  
YO Huh ◽  
EJ Freireich ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Myelodysplastic Syndrome ◽  
The Other ◽  
Initial Presentation ◽  
Cytogenetic Abnormality ◽  
Blast Count ◽  
Time Of Presentation ◽  
Current Standards

We report five patients who had greater than 30% peripheral blasts and less than 30% marrow blasts. By the current standards these cases would be classified as myelodysplastic syndrome. Four of five patients progressed to acute leukemia within approximately 1 1/2 months of developing greater than 30% peripheral blasts. Two of these four patients had evidence of acute leukemia by criteria other than marrow involvement at the time of presentation: one patient had evidence of multifocal dermal involvement; and the other patient had a cytogenetic abnormality, t(8;21), found predominantly in acute leukemia. The fifth patient developed acute leukemia 2 years after initial presentation with greater than 30% peripheral blasts. Although our series of patients is small, it does suggest that patients who have greater than 30% peripheral blasts should be considered an acute leukemia, even with less than 30% marrow blasts.

Sign in / Sign up

Export Citation Format

Share Document